PaloBiofarma
A company with the ambition to develop new treatments for cancer and autoimmune diseases based on adenosine receptor modulation.
Get premium to view all results
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (50 %) | (94 %) | 1567 % | (93 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 100 % | 100 % | (167 %) | 100 % | (114 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
More about PaloBiofarma
EditDeveloper of drugs intended to cure diseases based on the modulation of adenosine receptors. The company focuses to discover the first marketed drug based on a selective adenosine receptor modulator leveraging medicinal chemistry and in vitro pharmacology of adenosine, enabling doctors to focus on the treatment of advanced prostate cancer.
Keywords: Pharmaceuticals and Biotechnology, Adenosine Pharmaceutical, Adenosine Receptor, Cancer Therapy, Cancer Treatment, Clinical Development, Medical Services.
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.